PhRMA Wary Of Large Simple Safety Trials, Tells FDA Not To Create Phase III+
Executive Summary
Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9
You may also be interested in...
Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says
Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency
Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says
Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency
Dose Ranging Study In Phase III Could Bolster Rx Safety Profile, Temple Says
Evaluating a range of doses in Phase III clinical trials could bolster the safety profile for an investigational new agent, FDA Office of Medical Policy Director Robert Temple, MD, said April 9